Zipalertinib Plus Chemotherapy Significantly Extends Survival in Advanced Lung Cancer

A landmark clinical trial demonstrates that combining zipalertinib with platinum-pemetrexed chemotherapy significantly improves progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. This finding, presented at the International Association for the Study of Lung Cancer 2026 World Conference, represents an important advancement for first-line treatment options in this specific genetic subtype of lung cancer. EGFR exon 20 insertions represent a challenging mutation pattern that historically has had limited targeted therapy options. This combination therapy offers patients with this mutation profile better disease control and delayed cancer progression. The results provide hope for improved outcomes in a patient population that previously had fewer effective treatment alternatives.